Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support.

BACKGROUND The main risk factor for bleeding in patients with continuous-flow mechanical circulatory support (CF-MCS) is the acquired von Willebrand factor (VWF) defect related to the high shear-stress forces developed by these devices. Although a higher bleeding rate has been reported in CF-MCS recipients who had reduced pulsatility, the relation between pulsatility and the VWF defect has never been studied. OBJECTIVES The purpose of this study was to investigate the relation between pulsatility and VWF under CF-MCS. METHODS We assessed the effect of 2 CF-MCS on VWF multimer degradation in a mock circulatory loop (model 1). Using these devices, we investigated in a dose-effect model (model 2) 3 levels of pulsatility in 3 groups of swine. In a cross-over model (model 3), we studied the effects of sequential changes of pulsatility on VWF. We reported the evolution of VWF multimerization in a patient undergoing serial CF-MCS and/or pulsatile-MCS. RESULTS We demonstrated the proteolytic degradation of VWF multimers by high shear CF-MCS in a circulatory loop without pulsatility. We observed both in swine models and in a patient that the magnitude of the VWF degradation is modulated by the pulsatility level in the high shear-stress level condition, and that the restoration of pulsatility is a trigger for the endothelial release of VWF. CONCLUSIONS We demonstrated that the VWF defect reflects the balance between degradation induced by the shear stress and the endothelial release of new VWF triggered by the pulsatility. This modulation of VWF levels could explain the relationship between pulsatility and bleeding observed in CF-MCS recipients. Preservation of pulsatility may be a new target to improve clinical outcomes of patients.

[1]  F. Kallel,et al.  Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  G. Ewald,et al.  Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure , 2017, Circulation.

[3]  Antoine Capel,et al.  The Carmat Bioprosthetic Total Artificial Heart Is Associated With Early Hemostatic Recovery and no Acquired von Willebrand Syndrome in Calves. , 2017, Journal of cardiothoracic and vascular anesthesia.

[4]  F. Mouquet,et al.  Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. , 2015, Circulation research.

[5]  Snehal R. Patel,et al.  Creating adequate pulsatility with a continuous flow left ventricular assist device: just do it! , 2016, Current opinion in cardiology.

[6]  Myron N. Chang,et al.  The Incidence, Predictors and Outcomes of Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device (LVAD) , 2015, Digestive Diseases and Sciences.

[7]  E. Belle,et al.  Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis , 2015, Journal of thrombosis and haemostasis : JTH.

[8]  G. Lemesle,et al.  Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. , 2016, The New England journal of medicine.

[9]  Gregory J. Stoddard,et al.  Pulsatility and the Risk of Nonsurgical Bleeding in Patients Supported With the Continuous-Flow Left Ventricular Assist Device HeartMate II , 2013, Circulation. Heart failure.

[10]  D. Tassaux,et al.  Veno-venous extracorporeal membrane oxygenation: cannulation techniques. , 2016, Journal of thoracic disease.

[11]  Gregory A. Ewald,et al.  A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure , 2017, The New England journal of medicine.

[12]  K. Muthiah,et al.  Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  G. Remuzzi,et al.  Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. , 1997, Blood.

[14]  C. Bara,et al.  Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. , 2014, JACC. Heart failure.

[15]  Wei Li,et al.  Hypertensive stretch regulates endothelial exocytosis of Weibel-Palade bodies through VEGF receptor 2 signaling pathways , 2013, Cell Research.

[16]  S. Susen,et al.  Acquired von Willebrand syndrome in aortic stenosis. , 2003, The New England journal of medicine.

[17]  N. Uriel,et al.  Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. , 2010, Journal of the American College of Cardiology.

[18]  Andrew Boyle,et al.  Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. , 2009, The Journal of thoracic and cardiovascular surgery.

[19]  Young Choi,et al.  Rotary pump speed modulation for generating pulsatile flow and phasic left ventricular volume unloading in a bovine model of chronic ischemic heart failure. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  M. Mehra,et al.  Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  Steven C. Koenig,et al.  Defining pulsatility during continuous-flow ventricular assist device support. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  Yoshifumi Naka,et al.  Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). , 2011, Journal of the American College of Cardiology.